P00008997A0472|4 6|CSF
P00008997A0472|8 11|HCO3
P00008997A0472|34 41|CSF PCO2
P00010943A0733|0 9|Flurazepam
P00015731A0090|11 24|administration
P00015731A0090|44 63|anhydrase inhibitors
P00015731A0090|92 107|dichlorphenamide
P00022143T0000|20 30|etoperidone
P00024600A0522|11 28|HMG dosage regimen
P00025557A0100|7 17|CO2 content
P00027739T0000|0 30|Serum gamma glutamyltransferase
P00027967A0207|20 32|HI antibodies
P00029555A0861|102 136|shellfish microbiology laboratories
P00030183T0000|33 38|HLA-B5
P00030937A0119|13 47|alkaline phosphatase concentrations
P00033873T0001|0 28|Gamma glutamyl transpeptidase
P00034935A0545|0 7|Patients
P00034935A0545|12 20|Parkinson
P00038408T0000|89 91|FLA
P00039271T0000|49 59|application
P00048373A0377|0 6|Removal
P00050628A0202|2 4|IgG
P00052597T0000|48 63|Professor Dan H.
P00055040A0000|158 167|FR-antigen
P00055040A0000|238 240|HPF
P00056901A0308|27 46|hydroxy-ethyl-starch
P00060529A0695|75 85|0acteriuria
P00060529A0695|145 163|practice population
P00066874T0000|21 50|fluid alpha fetoprotein levels
P00073344A0367|14 36|phytomitogen reactivity
P00083846T0000|16 25|AMP levels
P00086313A0000|20 31|Legionnaires
P00088391A0181|43 60|coumarin treatment
P00089778A0000|84 114|fibrinogen degradation products
P00089778A0000|114 116|FDP
P00092689A0352|12 19|patients
P00094639A0313|0 7|Prazosin
P00096241A0087|5 8|FT4I
P00096241A0087|136 138|EGA
P00097989A0106|23 37|treatment plans
P00100540T0000|0 18|Aspirin intolerance
P00100791A0425|24 41|cynomolgus monkeys
P00105903A0288|67 69|PEG
P00111174A0351|26 35|properties
P00112627A0542|0 12|Pentobarbital
P00113657A0628|0 6|Pb foil
P00114144A0189|136 159|glycogen storage disease
P00117748T0000|38 64|Corynebacterium diphtheriae
P00118044A0000|89 96|M3 peaks
P00118044A0000|115 126|EMG activity
P00119339A0400|75 89|T. cruzi stocks
P00122718A0500|13 21|MRF units
P00129659T0000|79 81|IQs
P00131739T0001|48 57|Uzbekistan
P00133214T0064|40 43|USSR
P00136175A1137|153 155|ECA
P00137671A0896|50 59|VIII-ratio
P00139624A0318|48 72|serum ceruloplasmin level
P00139827A0000|0 16|Radioimmunoassays
P00139827A0000|45 66|dehydroepiandrosterone
P00139827A0000|68 70|DHA
P00142718A0156|93 102|99mTc-EHDP
P00146327A0147|110 121|stem bronchi
P00149899T0001|0 9|Prediction
P00154430A0906|3 20|Southern technique
P00155973A0387|116 143|carbon dioxide concentration
P00155973A0387|213 230|minute ventilation
P00159600A0871|0 1|SV
P00159600A0871|17 19|SHR
P00159600A0871|84 86|SHR
P00163384A0000|28 43|Bubo virginianus
P00167544A0067|157 182|surface specimen technique
P00168176A0000|22 41|apple butter samples
P00168431T0000|0 19|Steroid glucuronides
P00172199A0270|101 116|cross striations
P00173860A0475|0 9|Riboflavin
P00173860A0475|80 97|excretion patterns
P00176742T0000|0 10|Polyglactin
P00183063A0300|14 27|DNCB reactions
P00183063A0300|42 46|Stage
P00183063A0300|95 99|Stage
P00183063A0300|172 176|Stage
P00188387A0975|75 76|FH
P00193088A0196|34 43|Metyrapone
P00193587T0000|0 14|EEG theta waves
P00196255A0000|0 16|REM dream content
P00198510T0000|44 61|Locusta migratoria
P00201881A0487|63 69|PI ACTH
P00201881A0487|72 83|MSH contents
P00205074A0000|7 22|hypophosphatemia
P00209664A0836|132 149|parallel phenomena
P00211881A0602|126 128|PBB
P00216939T0001|45 72|acid dehydrogenase reactions
P00219533T0001|0 11|Distribution
P00219565A0172|14 32|hepatitis B antigen
P00219674A0000|0 13|Technetium-99m
P00221725A0523|25 42|cytochrome oxidase
P00222102A0227|24 52|pseudohypoparathyroidism type
P00222102A0227|72 99|alpha-Hydroxycholecalciferol
P00222827A0000|46 48|TDI
P00224013A0661|5 7|VO2
P00224013A0661|294 310|extraction ratios
P00224013A0661|335 360|beta-Vasodilator receptors
P00225352T0000|50 51|3H
P00227610A1593|31 38|DBP mRNA
P00232354A0286|0 9|Serum ACTH
P00232456T0000|12 14|RNA
P00232456T0000|32 35|MC29
P00232456T0000|39 41|MH2
P00234264A0164|0 37|Gamma glutamyl transpeptidase activity
P00239014A0000|79 82|CPIB
P00239169T0000|0 25|Dopamine receptor blockade
P00240518A0000|51 76|fungicide 5-fluorocytosine
P00261981A0434|18 36|serum somatomedin A
P00264240A1843|152 174|X. laevis oocyte 5S DNA
P00267764A0651|40 57|treatment failures
P00300314A0132|54 76|degrees F. granulocytes
P00300314A0132|149 166|calcium leucovorin
P00303189A0247|45 59|serum chemistry
P00304310A0000|76 88|stabilization
P00304806A0760|12 38|serum alpha1AT quantitation
P00313766A0666|53 62|depression
P00321261A0104|36 39|PGE2
P00321261A0104|44 64|prostaglandin F2alpha
P00330364A0132|10 20|BCG strains
P00330364A0132|74 76|BCG
P00330364A0132|138 152|BCG-vaccination
P00330364A0132|183 197|BCG-vaccination
P00331128A0000|12 27|serum calcitonin
P00331936T0000|44 80|immunoperoxidase antiglobulin technic
P00336354A0543|22 38|arginine infusion
P00336547A0000|67 98|Nocardia brasiliensis infections
P00339289T0049|0 2|Use
P00342623A0228|20 39|whole-virus vaccines
P00352569A0000|30 45|blood parameters
P00354315T0000|32 52|ataxia telangiectasia
P00361059T0000|32 54|diflucortolone valerate
P00361059T0000|69 89|clobetasol propionate
P00361340A0529|114 142|1,25-dihydroxycholecalciferol
P00369683T0000|0 9|Adriamycin
P00377466A0188|38 39|LH
P00377466A0188|42 69|follicle stimulating hormone
P00377466A0188|69 71|FSH
P00377466A0188|84 87|HPRL
P00378492A0475|122 145|plasma aldosterone level
P00378735A0000|128 142|dosage schedule
P00378735A0000|188 202|chloramphenicol
P00378735A0000|226 245|temperature response
P00383169A0000|46 62|dopamine receptor
P00383169A0000|119 139|rye-ergot derivatives
P00386251A0899|3 21|IDF standard method
P00386251A0899|83 103|sulphonamide residues
P00393598A0198|47 49|ALS
P00413854A0958|0 6|Changes
P00415543A0320|0 10|Recognition
P00416758T0001|11 30|T. gambiense strains
P00420460A0291|48 81|log baseline plasma renin activity
P00425547A0000|21 33|osteomyelitis
P00427715A0000|125 134|University
P00429151T0000|59 70|Glasgow area
P00429893A0000|109 121|scala tympani
P00429949A0000|61 86|Biological Standardization
P00429949A0000|161 195|International Reference Preparation
P00437749A0242|7 26|treatment modalities
P00439618T0001|0 16|Lethal Tachmalcor
P00439716T0001|32 50|blood flow velocity
P00445720A0263|91 124|high-fidelity pressure transducers
P00450559A0269|43 51|Clinitemp
P00451192A0248|100 120|LV region-of-interest
P00453780A0430|15 32|serum IgA response
P00453780A0430|44 61|patient population
P00454780A0340|0 18|Ultimate strengthes
P00463973A0000|0 14|Platelet number
P00463973A0000|120 122|SGA
P00464387A1185|75 78|ABPA
P00465223A0373|17 35|difference betweent
P00465223A0373|90 91|SD
P00465681A0000|7 30|hemoglobin concentration
P00465681A0000|106 120|oxygen pressure
P00465829T0000|8 30|Planck analog equations
P00474064A0205|18 37|convlusion threshold
P00474064A0205|177 180|I.V.
P00476020T0000|3 14|biochemistry
P00476572A0139|113 124|radiodensity
P00479222A0682|0 9|Resistance
P00479222A0682|143 146|PECF
P00483716A0366|57 70|carotid artery
P00484177A0242|76 83|CT value
P00485615A0935|158 169|pancreatitis
P00488534A0308|22 51|Treatment X Strain interaction
P00490336A0181|5 23|conduction velocity
P00493818A0422|34 52|patient intolerance
P00494659A0391|52 80|hydroxymethyl-2-oxazolidinone
P00495097A0663|5 19|characteristics
P00495097A0663|63 77|fiber synthesis
P00499588T0000|0 22|Carbohydrate metabolism
P00503336A0285|16 19|CAEC
P00503336A0285|29 30|CC
P00503336A0285|34 37|CIEC
P00506559A0000|12 30|inhalation toxicity
P00513284A0000|38 41|DOTC
P00513284A0000|43 52|Vibramycin
P00513284A0000|191 194|DOTC
P00513284A1255|23 35|DOTC infusion
P00517890A0468|79 105|hepatitis A virus excretion
P00521732T0000|81 109|steroid sulphatase deficiency
P00524451A0136|22 39|locomotor activity
P00524451A0136|154 167|catecholamines
P00534613A0000|36 39|UV-A
P00540707A0255|215 230|PMK implantation
P00541752A1032|76 82|October
P00541752A1032|128 129|SD
P00553858A0000|8 12|Grice
P00555492A1034|152 165|blood pressure
P00555495T0000|0 4|Study
P00555495T0000|7 22|re-establishment
P00555583T0000|0 15|Pharmacokinetics
P00557559A0170|53 79|N-methylnitrone 1,4-dioxide
P00564032A0724|0 6|Changes
P00564943A0444|9 16|MCT-milk
P00564943A0444|71 78|SBO-milk
P00565136T0000|55 58|CH2O
P00565136T0000|60 65|SO2Cl2
P00565314A0293|0 10|Guinea pigs
P00569989A0239|75 103|acceleration pneumocardiogram
P00574956A0304|253 265|manifestation
P00577440A0298|60 81|3H-alpha-acetyldigoxin
P00580151A0706|61 72|testosterone
P00583004A0445|35 60|1,8,9-triacetoxyanthracene
P00587791T0054|0 6|Nursing
P00589073A0000|15 45|plasma prolactin concentrations
P00592887T0000|18 35|Patent Blue Violet
P00594466T0001|25 35|Papio papio
P00594617A0192|69 88|degradation products
P00594617A0192|89 91|FDP
P00594617A0192|193 217|ethanol-gelification test
P00594617A0192|275 277|ESR
P00597715A0256|0 8|One-third
P00597715A0256|79 91|FSH elevation
P00598012A0174|2 23|girls prolactin levels
P00601401A0181|96 123|delta log Po2/delta pH ratio
P00602622A0362|36 42|Vikalin
P00602622A0362|44 48|Roter
P00602702A0309|33 53|estriol concentration
P00602702A0309|108 128|estriol concentration
P00616575A0000|101 103|EMF
P00616575A0000|106 107|DW
P00618078A0367|14 30|lysozyme activity
P00619782A0058|73 93|ultraviolet radiation
P00619782A0058|94 97|UV-A
P00619948A0000|46 52|Motival
P00619948A0000|145 147|CNV
P00619948A0000|173 186|blood pressure
P00621626T0000|15 37|affiliation preferences
P00627039T0000|25 67|Louisiana paper manufacturing plant workers
P00627129A0944|174 191|beta-adrenoceptors
P00627202T0000|0 8|Diuretics
P00628990A0000|86 104|ureteroureterostomy
P00628990A0000|119 138|ureteroneocystostomy
P00633909A0000|43 65|Internal-External Locus
P00635143T0001|33 47|Cyprinus carpio
P00637637T0000|27 47|plasma renin activity
P00641395A0441|80 82|ZPP
P00644539A0783|53 56|FEV1
P00646193T0000|0 6|Potency
P00663166A0000|150 173|patent ductus arteriosus
P00663166A0000|181 202|Eisenmenger physiology
P00665336A0908|43 57|EEG-information
P00668122A0414|101 124|liver ferritin molecules
P00669800A0579|42 50|infection
P00681550A0000|0 6|Procion
P00681571T0028|54 77|eccrine sweat duct units
P00685922A0451|71 73|IHB
P00686836A0000|172 191|IU vitamin E acetate
P00693987T0001|0 13|Thromboplastic
P00693987T0001|52 65|administration
P00696680A0000|71 87|rhabdomyosarcomas
P00701462A0722|0 15|Urine antibodies
P00702773A0327|84 86|RBF
P00702773A0327|88 90|GFR
P00703932A0000|15 32|glomerulonephritis
P00704675A0199|9 11|UO2
P00710372A0302|82 94|GH deficiency
P00712117A0521|49 56|February
P00712117A0521|71 79|A/Texas/1
P00712117A0521|107 118|A/Victoria/3
P00713525A0268|21 36|disfluency rates
P00715180T0074|53 81|plutonium-239 dioxide aerosol
P00716366T0001|22 52|alkaline phosphatase isoenzymes
P00722298A0619|102 117|field dependence
P00722298A0619|124 135|significance
P00722652A0118|11 34|2nd-generation schizonts
P00725257A0452|40 42|DHE
P00725336T0000|0 35|Newcastle disease virus surveillance
P00725534A0888|40 48|M. leprae
P00725534A0888|66 80|IgA immunocytes
P00725534A0888|139 152|IgA deficiency
P00725752T0001|54 76|beta receptor blockader
P00733067A0188|246 264|spiral introflexion
P00737422A0832|0 8|Pathogens
P00741476A0000|24 42|Ergotamine Tartrate
P00743335T0001|0 13|Reaction times
P00747722A0486|40 51|B1 injection
P00747722A0486|52 56|Phase
P00748978T0000|0 19|Serum relaxin levels
P00753237A0000|90 93|PAIN
P00753237A0000|162 164|PPU
P00753237A0000|190 202|INSENSITIVITY
P00753237A0000|206 214|TRAUMATIS
P00753237A0000|325 340|PNEUMATIC INSOLE
P00753237A0000|481 483|PPU
P00755245A0000|0 5|Effect
P00755671A0485|40 60|recalcification times
P00755869A0216|0 22|Contingency contracting
P00756511T0036|0 8|Dietetics
P00759049A0185|60 88|bathophenanthroline chromogen
P00759400T0000|0 17|Platelet serotonin
P00762763A0253|21 24|SIDS
P00767161A0837|26 47|serum E2 concentration
P00779272T0001|61 73|mononucleosis
P00780639X0000|24 26|CEA
P00792847A0000|21 43|antilymphocyte globulin
P00799988A0554|19 37|assessment patients
P00803867A0315|0 7|Patients
P00806295A0193|0 9|Absorption
P00808898A0000|79 82|IPRF
P00819176T0001|81 101|Anomalocera patersoni
P00819176T0001|102 122|Pontella mediterranea
P00819176T0001|123 143|Labidocera wollastoni
P00821833A0000|64 80|Alouatta palliata
P00822611A0467|77 89|binephrectomy
P00827364A0000|32 48|freeze-fracturing
P00830568A0000|70 72|LTM
P00830568A0000|160 165|STG-BI
P00830568A0000|191 197|STG-BII
P00833472A0907|90 105|gallbladder bile
P00836637A0000|111 132|arithmetic performance
P00836637A0000|134 145|EMR children
P00837262A0000|113 115|OFF
P00837811A0675|56 86|fluid gamma globulin elevations
P00838152A0863|14 34|mean temperature rise
P00839378A0649|21 29|RDS group
P00842406A0771|57 79|visuomotor coordination
P00846559A0000|30 48|F. sporotrichioides
P00846559A0000|96 118|F. sporotrichioides var
P00851041A0000|31 37|Ebstein
P00851286A0375|0 5|Deaths
P00851286A0375|25 45|copper concentrations
P00857024A0888|0 9|Recurrence
P00863184T0043|0 9|Adaptation
P00866577A0579|0 8|Treatment
P00866577A0579|21 42|plasminogen activators
P00868301A0043|41 72|2-benzylidenamio-1-phenylpropane
P00868903A0000|0 7|Amikacin
P00870859A0121|71 83|recirculation
P00872442T0000|44 69|LKB reaction rate analyser
P00877857A0763|40 48|CU/100 ml
P00879329A0176|5 23|control preparation
P00879329A0176|148 150|IIp
P00879829A0564|36 38|IVH
P00881630A0000|49 61|A. piscivorus
P00881630A0000|90 104|Phospholipase-A
P00885562A0281|5 8|GAGs
P00885562A0281|121 133|GAG synthesis
P00890028A0507|51 65|Reynolds number
P00890028A0507|104 120|Taylor microscale
P00890028A0507|140 156|Kolmogoroff scale
P00891370A0000|52 66|xeroradiography
P00891370A0000|94 108|contrast-medium
P00898500A0246|56 57|HD
P00898500A0246|114 117|RAST
P00898500A0246|143 163|IgE antibody activity
P00903772A0359|20 43|conditioning stimulation
P00909114A0000|0 17|Diallylnitrosamine
P00909114A0000|19 21|DAN
P00911590T0000|54 81|atropine-neostigmine mixture
P00913623A0242|69 72|EHDP
P00915090A0536|39 44|Tc-99m
P00916099A0000|0 16|Self-emasculation
P00917572T0001|0 10|Possibility
P00917721A0484|52 71|presleep suggestions
P00918556A0000|15 41|hepatitis B surface antigen
P00918556A0000|97 123|radio-immunoassay technique
P00918965A0728|171 174|PAO2
P00921911A0159|12 14|PGF
P00921911A0159|18 21|PGFM
P00926272A0000|25 37|deterioration
P00926604A0504|0 10|Propranolol
P00926604A0504|12 18|Inderal
P00927633T0001|74 86|Rattus rattus
P00928529T0001|0 15|Feeding behavior
P00929418T0001|9 37|infectious-disease specialist
P00930947A0629|13 29|drug interactions
P00930947A0629|78 80|PZA
P00935526A0000|39 40|PG
P00938594A0149|106 108|HOA
P00938594A0149|169 170|RA
P00941050T0000|17 39|procainamide absorption
P00947327A0000|138 140|SMZ
P00947327A0000|155 157|TMP
P00947327A0000|325 337|2,4-diamino-5
P00947327A0000|340 362|3,4,5-trimethoxy-benzyl
P00947327A0000|403 404|CN
P00947327A0000|455 461|TMP/SMZ
P00951909X0001|135 157|Billroth-II gastrectomy
P00952734T0000|90 93|PECL
P00954819A1041|128 140|AChE activity
P00956554A0414|45 65|solid-phase allergens
P00956554A0414|95 108|IgE antibodies
P00959656A0250|39 50|antithrombin
P00961711T0000|0 17|Hematology problem
P00962222A0633|67 93|erythrocyte characteristics
P00962277T0000|0 12|Haemodilution
P00970320A0000|33 62|chemical cartridge respirators
P00970488A0105|39 49|DA turnover
P00970488A0105|75 94|DA receptor blocking
P00970839A0118|0 12|Rainbow trout
P00974901A0080|39 64|Bordetella pertussis cells
P00975314T0001|82 95|gonadoblastoma
P00975540T0000|75 96|high-accuracy analyses
P00980255T0000|16 39|2-deoxy-D-glucose method
P00984209A0614|52 90|background serum gastrin concentrations
P00985110T0001|8 18|projections
P00985276A0000|22 55|postflight exercise response tests
P00985279A0493|15 39|hemoglobin concentrations
P00985279A0493|91 99|CO2 group
P00986800A0325|3 11|Cu values
P00986800A0325|55 70|saturation level
P00986925A0002|80 111|plasma 47Ca radioactivity curves
P00987649T0001|0 4|State
P00988572A0000|36 39|PLO2
P00988572A0000|121 149|catheter-tip oxygen electrode
P00989973A0000|16 38|plasma fibrinogen level
P00992316A0178|21 35|pressure curves
P00993176A0066|134 136|NH4
P00993176A0066|138 150|2SO4 solution
P00999494A0000|91 107|agent propranolol
P01000378T0000|33 54|insulin concentrations
P01003819A0498|66 82|corneal curvature
P01004298A0744|34 45|CA component
P01009451A0728|23 24|UB
P01009451A0728|28 35|OCS rats
P01009739T0001|50 52|ECG
P01012904A0333|13 31|interference effect
P01012904A0333|82 92|Stroop test
P01019207A0232|113 126|mug ruscogenin
P01021091T0000|110 120|Octapressin
P01035457A0623|20 35|nipple discharge
P01036714A0072|0 6|Studies
P01036714A0072|123 137|cell population
P01044338A0240|22 40|temperature changes
P01047895T0001|63 70|Patients
P01050144A0297|114 124|83A complex
P01050400T0000|0 10|Improvement
P01050400T0000|13 31|nursing instruction
P01078982A0227|109 126|ALG administration
P01081904A0198|59 80|pull-out arteriography
P01082726A0248|44 49|DC-ERG
P01082833A0000|96 97|IM
P01082833A0000|160 176|carrageenin edema
P01083321X0000|47 59|subalpine fir
P01083321X0000|115 126|productivity
P01083784T0000|0 24|Lymphocyte subpopulations
P01084413A0271|43 45|EMI
P01087288T0000|93 109|thyroid carcinoma
P01088654T0001|0 8|Technique
P01090210A0417|0 3|Mean
P01090210A0417|95 113|mean closing volume
P01093845A0208|0 13|Modern studies
P01093845A0208|27 37|Delta-9-THC
P01093847A0000|21 45|tropatepine hydrochloride
P01098179A0167|0 6|Results
P01098179A0167|76 93|dissolution curves
P01098592A0567|0 9|IgG levels
P01107226A0808|83 98|mg/ml dose level
P01113908A0475|30 40|transferrin
P01116254A0000|20 33|administration
P01116254A0000|63 81|tracer thallium-201
P01116466A0185|0 18|Thromboplastin time
P01116466A0185|117 120|VIII
P01118293A0150|27 37|suppression
P01119586A0337|0 19|Glycogen utilization
P01119586A0337|67 69|ATP
P01119658A0000|177 197|lymph node metastases
P01123658A0000|137 139|L-4
P01124944A0830|28 39|protein diet
P01130186A0568|47 61|insulin release
P01130531A0224|0 16|Nerve stimulation
P01130531A0224|71 73|CBF
P01131946T0001|19 28|Norbiogest
P01138215T0001|0 3|Risk
P01138330A0204|52 56|N HC1
P01138330A0204|110 131|acetylcholine chloride
P01140184A0342|0 15|Liver microsomes
P01140184A0342|48 71|epoxide hydrase activity
P01141114A0188|76 79|PH-v
P01141114A0188|99 104|Pv-CO2
P01156631A0658|3 34|mean plasma sodium concentration
P01156814T0000|49 70|thromboembolic disease
P01157614T0000|32 54|matrix task performance
P01159822A0353|71 84|ultrastructure
P01159822A0353|91 103|invaginations
P01168607A0672|86 101|prothrombin time
P01168908A0000|0 15|Prostaglandins F
P01168908A0000|16 18|PGF
P01168908A0000|175 200|plasma progesterone levels
P01168956A0552|121 143|maximum weight decrease
P01170143A0247|0 5|Groups
P01171935A0313|134 167|dopamine receptor site sensitivity
P01172917T0000|7 29|Lactose tolerance tests
P01174873T0000|0 13|Retinoblastoma
P01176905A0094|20 34|serum melatonin
P01185956A0722|33 52|Doppler-cardiography
P01186344A0303|53 67|characteristics
P01190120A0832|39 57|thromboplastin time
P01190251A0335|0 6|Caution
P01191955A0077|36 47|incompetence
P01191964A0000|253 284|serum thyrotrophin concentration
P01193458T0001|33 49|Tc sulfur colloid
P01202616A0466|91 104|lamina propria
P01208811T0001|49 77|citrate solution-blood system
P01209618A0409|0 9|Tobramycin
P01209618A0409|76 94|potentiating effect
P01215067A0000|98 117|meningitis purulenta
P01215067A0000|127 143|meningitis serosa
P01217450A0295|2 19|Chemical occlusion
P01228258A0000|25 30|OK-432
P01228258A0000|135 154|Cytosine arabinoside
P01228882A0437|63 81|CSF immunoglobulins
P01237206A0199|0 12|Demonstration
P01237206A0199|146 161|Coxiella content
P01241437A0152|42 47|NLA II
P01241588A1470|23 35|5-HIAA levels
P01241588A1470|102 105|IDPN
P01241866A0682|15 30|leukocyte-counts
P01242636A0678|81 99|beryllium retention
P01243628A0286|44 66|blood carboxyhemoglobin
P01243628A0286|67 70|COHb
P01244236A1122|165 184|vasomotor reactivity
P01245162A0262|0 8|Reduction
P01245162A0262|109 127|transaminase levels
P01246210A0648|49 52|TBCa
P01247475A0000|16 29|retinoblastoma
P01249198A1097|80 91|GTD patients
P01252223A0347|59 76|trait correlations
P01252223A0347|101 105|Winch
P01253191T0000|10 45|phase-plane technique representation
P01256410T0001|1 10|activities
P01259027A0416|23 37|identifiability
P01259027A0416|79 94|model parameters
P01261005A0711|93 119|bandpass spectrophotometers
P01265443A0159|45 65|Heidenhain pouch dogs
P01267446A0210|0 15|Biohydrogenation
P01272816A0000|10 27|calcium metabolism
P01275541A0405|21 32|CPK activity
P01276105A0313|14 29|insulin response
P01278251A0000|109 128|tetraphenylbutadiene
P01278251A0000|130 132|TPB
P01279197T0000|44 68|Mason-Pfizer monkey virus
P01279352A0473|124 127|PROX
P01279352A0473|131 143|PAL sequences
P01279352A1197|16 17|NF
P01279352A1197|133 164|beta-galactosidase reporter gene
P01279374A0396|118 123|PET122
P01280413T0001|0 8|Treatment
P01281322A0604|51 70|percent area density
P01281771T0000|0 15|Characterization
P01282638A0934|3 18|prophylactic use
P01282638A0934|137 153|health care costs
P01282638A0934|279 293|life expectancy
P01284032A0213|0 1|AP
P01284032A0213|84 87|GDOC
P01284595A0102|94 104|HTF islands
P01284828T0001|0 27|Tissue plasminogen activator
P01285009A0000|0 14|Gene constructs
P01285009A0000|90 110|mouse metallothionein
P01285009A0000|142 160|rat cholecystokinin
P01285009A0000|169 186|chicken beta-actin
P01285358A0396|0 12|Serum gastrin
P01285358A0396|15 24|AFP levels
P01285807A0365|11 12|SD
P01285807A0365|14 17|PaO2
P01285807A0365|99 103|PaCO2
P01286732A0572|134 152|liver cell necrosis
P01286732A0572|186 206|P. falciparum malaria
P01287197A0761|37 52|plasma potassium
P01294345A0591|60 68|Bromergon
P01295373A0651|46 58|% baseline RL
P01295373A0651|65 66|SE
P01295500A0366|47 53|Attacks
P01295500A0366|89 96|Deficits
P01296815A0059|42 51|LD78 gamma
P01297332A0983|44 47|SCBs
P01297332T0000|21 32|DNA sequence
P01298173A0153|98 109|chemotherapy
P01299489A0788|128 131|RDIs
P01300914A1066|191 194|ACRV
P01300914A1066|320 321|VT
P01300914A1066|448 464|amplification ECG
P01300914A1066|611 626|RV abnormalities
P01301171A0979|35 57|c-myc bearing sequences
P01304809T0001|24 52|Friedrich Schiller University
P01309587A0715|31 44|BMRF1 promoter
P01309593A1092|20 24|UCRBP
P01309593A1092|73 81|UCR motif
P01309815A0972|130 142|AEP synthesis
P01309894A0807|31 42|AAV sequence
P01310154A0879|89 99|FBR protein
P01310154A0879|203 213|FBR protein
P01310178A0876|3 30|JS78 mutation changes Gln243
P01310178A0876|162 188|host transcription shut-off
P01310879A0000|56 58|HAT
P01310899A0339|133 162|serine/threonine kinase domain
P01312005A0600|0 7|Analysis
P01312005A0600|49 52|MDP1
P01312005A0600|285 286|OH
P01313715A0461|97 100|HL60
P01313715A0461|171 192|B-lymphocyte cell line
P01313715A0461|192 198|EBV-BCL
P01313715A0461|229 239|CGD patient
P01313846A0850|63 93|immunoglobulin gene superfamily
P01313894A1179|54 74|LMP2B mRNA expression
P01313909A0526|18 38|ICP0 nonsense mutants
P01314457T0000|68 70|HVS
P01314457T0000|125 127|HVS
P01314841A0724|13 18|MK-801
P01314841A0724|48 50|EEG
P01314953A1266|11 40|gel mobility shift experiments
P01316125A0382|54 57|YHPD
P01316125A0382|110 111|OH
P01316125A0382|115 118|YHPD
P01316125A0382|164 167|YHPD
P01316125A0382|188 191|BHPD
P01316125A0382|296 297|OH
P01316461A1083|23 32|S2 protein
P01316461A1083|67 68|S2
P01316476A1428|3 5|ORF
P01316476A1428|40 42|ORF
P01316680A0643|63 75|CAYWCCLGHAFAC
P01316680A0643|101 127|consensus zinc finger motif
P01316903A0296|25 38|RNA polymerase
P01316903A1040|0 17|RNA polymerase IIA
P01316903A1040|97 114|RNA polymerase IIA
P01317376A0981|0 20|Fructokinase activity
P01320255A0795|74 84|L1 sequence
P01320640A0336|80 82|VIP
P01321277A0342|71 96|chicken embryo fibroblasts
P01321277A0664|0 2|ROS
P01321277A0664|4 6|SRC
P01321280A0494|95 125|immunoprecipitation experiments
P01321332A0970|69 71|RXR
P01321332A0970|168 169|RA
P01321332A0970|241 245|ARP-1
P01321336A0731|19 27|ALF1 cDNA
P01321337A0318|101 105|45Ca2
P01321337A1161|26 39|MATa cna1 cna2
P01321337A1161|52 68|MATa cnb1 mutants
P01324172A0880|44 47|RIM1
P01324404A0813|114 131|HNF-3 beta protein
P01324404A1208|0 9|HNF-3 beta
P01324404A1208|139 158|region II-III domain
P01324406A1250|27 54|ATPase/DNA helicase activity
P01324639T0000|0 15|Susceptibilities
P01324639T0000|85 107|amoxicillin-clavulanate
P01325386A0766|49 66|heat shock protein
P01326329A0703|193 224|glucocorticoid response elements
P01326329A0703|246 266|AMP response elements
P01326557T0000|74 105|chondroitin sulfate proteoglycan
P01327280A0000|75 90|cord dorsal horn
P01327967A0668|68 96|agent methylmethane sulfonate
P01328197A0985|27 64|MAP kinase activator/MAP kinase system
P01328219A1397|0 5|NSCL-1
P01328681A0149|47 67|c-myc hyperexpression
P01328854T0000|7 16|MEF-2 site
P01328854T0000|110 137|phosphoglycerate mutase gene
P01328884T0000|0 18|Truncation variants
P01329039A0239|45 50|CANNTG
P01330309A1134|3 15|CANNTG motifs
P01330309A1134|37 60|myogenin fusion proteins
P01331057A0000|24 28|COX12
P01331086T0000|32 59|cytochrome c oxidase subunit
P01331292A1425|44 58|oligonucleotide
P01331501A0397|105 108|p107
P01331501A0397|121 124|p130
P01331516A0103|26 51|3T6 mouse fibroblast cells
P01332589A0666|3 6|MICs
P01332964A0247|23 35|RII beta gene
P01333035T0000|10 43|cAMP receptor protein contact site
P01333047A0404|53 77|growth factor stimulation
P01333053A0110|22 59|steroid hydroxylase gene transcription
P01333125A0000|139 141|UTR
P01333317A1008|38 40|Sp1
P01333317A1008|98 102|PRF-I
P01334493A0289|20 23|HGFr
P01334493A0289|36 38|HGF
P01337142A2043|13 47|glycoprotein alpha-subunit promoter
P01338867A0503|0 9|Comparison
P01339125A0153|0 17|Laboratory studies
P01339373T0000|33 52|Arabidopsis thaliana
P01339373T0000|77 95|SNF1 protein kinase
P01339391A0000|42 62|DNA surrounding HRAS1
P01339468A0272|3 14|ORF1 protein
P01339468A0272|55 79|potexvirus RNA replicases
P01339773A0778|116 142|ventilation-perfusion ratio
P01340470A0000|67 87|RNA recognition motif
P01341119A0450|70 82|H2 inhibitors
P01346262A0377|53 70|S. entomophila UC9
P01346262A0377|78 81|UC21
P01346534T0000|0 15|Characterization
P01347664A1026|50 57|CAD mRNA
P01347908T0000|62 70|Parkinson
P01347944A0964|37 60|homeodomain binding site
P01348508A0313|153 161|TGM1 gene
P01348590A0000|110 120|HIV-disease
P01348590A0000|125 127|CD4
P01349837T0000|18 37|Arabidopsis thaliana
P01350780A0184|0 29|Amino acid sequence comparison
P01350932A1123|59 80|N-glycosylation sequon
P01352113A0002|53 54|NO
P01352113A0231|62 79|NO2 concentrations
P01357190A0726|38 59|membrane anchor domain
P01357528A0084|63 68|SEF-17
P01358190A0654|17 30|DR1 beta chain
P01358758A0000|87 99|FLAT elements
P01360180A0513|35 47|baculoviruses
P01360294A0000|4 9|August
P01360294A0000|16 22|October
P01363080A0710|95 113|agent metronidazole
P01363080A0710|143 162|anhydrase inhibitors
P01363166T0001|17 39|H2 receptor antagonists
P01364100A0377|18 36|subrepeat structure
P01370446A0818|26 57|keratan sulfate attachment sites
P01371181A0688|87 101|characteristics
P01371275T0000|55 60|ATPase
P01371413A0742|51 72|Southern blot analysis
P01371413A0742|104 127|rodent-human hybrid DNAs
P01372365A1202|34 35|Cl
P01372365A1202|37 50|concentrations
P01372456A0426|0 7|Necrosis
P01372456A0426|22 32|TA infusion
P01372802A1481|38 56|amino acid residues
P01372802A1481|155 166|C3 fragments
P01372802A1481|191 210|fluid-phase fragment
P01372900A0448|91 115|alpha s1-casein variant A
P01373374A0735|74 85|GBF3 binding
P01374331A0636|62 81|nuclease S1 analysis
P01374398A0951|10 28|translation protein
P01374398A0951|79 100|amino acid composition
P01374398A0951|138 156|amino acid residues
P01374688A0471|33 47|% pentafraction
P01374688A0471|96 110|micrograms/kg/0
P01375224A0152|71 96|chicken embryo fibroblasts
P01376319T0000|43 70|mannose 6-phosphate receptor
P01377696A0000|23 54|surface glycoprotein neurofascin
P01377696A0000|107 139|antibody perturbation experiments
P01377962A1012|11 22|tobacco GS-2
P01378052A0594|77 79|CAC
P01378052A0594|92 94|GTG
P01378052A0594|98 100|TGT
P01378052A0594|113 115|ACA
P01378506A0884|82 83|NC
P01378526A0535|29 47|FK506 plasma levels
P01379032A0495|62 73|steroid dose
P01379150A0996|157 172|risk arrhythmias
P01380062A0097|97 110|CTL clones Y-1
P01380076A0165|42 61|paired-ion technique
P01380716A0174|77 91|calcium hydrate
P01380825A0622|0 21|Northern blot analyses
P01383695A0100|12 27|EBV B-cell clone
P01384165A0000|50 64|vascularization
P01384165A0000|144 160|tracheal grafting
P01384229A0175|105 114|BF-IV gene
P01384229A0175|197 230|chloramphenicol acetyl transferase
P01385462A0151|103 120|acid determination
P01386210A0293|100 117|GM2 gangliosidosis
P01386897A0000|65 76|CDC28 kinase
P01386897A0000|121 124|CLN1
P01386897A0000|128 131|CLN2
P01387105A0933|7 28|Southern blot analyses
P01387105A0933|29 31|DNA
P01389573A1071|0 3|TBPf
P01389573A1071|73 76|TBPf
P01391001A0583|67 76|ATB method
P01392277A0000|113 127|KOK regulations
P01392277A0000|163 165|DIN
P01392358A0389|21 37|telephone contact
P01394200A0592|33 49|T-cell activation
P01394200A0592|166 171|CD45RO
P01394655A0615b|0 14|Urease activity
P01394655A0615b|101 121|Jack bean meal urease
P01395755A1023|137 151|oxygen delivery
P01395755A1023|220 224|L/min
P01395755A1023|236 240|L/min
P01396432A0388|94 111|memory performance
P01396444A0934|72 73|AM
P01396444A0934|95 111|activation states
P01396572A0320|87 88|CG
P01396592A1113|62 88|transcription factor GATA-1
P01396592A1113|97 112|SCL gene product
P01396601A0986|30 35|Sec12p
P01398068A0948|98 113|RGC DNA sequence
P01398071A0526|77 89|BRF1 activity
P01398071A0526|130 144|RNA polymerases
P01398073A0986|54 66|TFIID protein
P01398074A0697|75 103|RNase MRP enzyme preparations
P01398074A1081|3 20|RNase MRP RNA gene
P01398098A0770|0 19|Clone pSRc200 hybrid
P01398104A0834|17 21|CBF-A
P01398104A0834|30 37|CArG box
P01398106A0754|0 7|Cleavage
P01398106A0754|63 83|intron insertion site
P01398106A0754|186 195|OH termini
P01398140A0488|16 30|Xenopus U7 gene
P01398140A0488|104 106|PSE
P01400217T0000|29 66|IncP alpha plasmid transfer genes traF
P01400396A1265|109 129|protein kinase C beta
P01400401A0065|13 34|AMP deaminase variants
P01400401A0854|0 20|Western blot analyses
P01400775A0435|66 83|N-methylsalsolinol
P01402647A0114|0 12|DR1 molecules
P01403222A0391|73 86|blood donation
P01406630A0545|165 177|DNA sequences
P01406630A0965|12 14|p50
P01406630A0965|152 169|NF-kappa B complex
P01406656A1075|96 98|DNA
P01406677A0000|150 169|nucleotide positions
P01406688A0898|0 18|Sequencing analysis
P01406703A1435|12 31|Y1 cell cDNA library
P01407286A0427|0 6|Autopsy
P01407286A0427|146 165|tyrosine hydroxylase
P01408090A0572|17 33|TEE visualization
P01408137A0974|32 42|G+C content
P01408219A0670|60 62|PGL
P01409581A0206|18 20|E26
P01409643A0618|99 110|TATA element
P01409643A0618|205 216|TATA element
P01410071T0000|0 11|Blood levels
P01410071T0000|86 110|platelet serotonin uptake
P01413984A0737|30 47|FA supplementation
P01413984A0737|160 190|plasminogen activator inhibitor
P01413984A0737|190 217|tissue plasminogen activator
P01413984A0737|219 253|von Willebrand factor concentration
P01414219A0319|59 84|peak plasma concentrations
P01418272A1072|39 41|CEA
P01418542A0000|38 40|SGA
P01418834A0987|12 30|hematocrit decrease
P01418834A0987|71 84|blood pressure
P01418860A0797|165 188|calcium channel blockade
P01419945A1386|0 11|Localization
P01420177A1065|0 11|Substitution
P01420363A0818|3 6|TIMP
P01420363A0818|16 23|AP1 site
P01420363A0818|127 137|AP1 factors
P01420363T0000|19 36|PEA3 binding sites
P01420579A0292|23 24|SN
P01420579A0292|84 94|SN antibody
P01421145A1190|37 66|heparin-agarose chromatography
P01421390T0000|141 167|bone marrow transplantation
P01421609A1067|24 27|DMVA
P01421609A1067|64 66|CPB
P01422265A0263|3 22|IgG subclass profile
P01423454A0309|0 10|Examination
P01423454A0309|13 16|ANCA
P01423738A0639|129 142|mean delta tau
P01425653T0000|23 40|caffeine ingestion
P01425653T0000|60 77|oxygen consumption
P01427034A0440|120 132|DNA sequences
P01427457A0000|76 77|SC
P01427457A0000|188 190|DVT
P01428490A0671|30 40|pet allergy
P01429596A1669|88 123|18K agglutination-aggregation factor
P01429624A0328|97 111|adenylylcyclase
P01429740A1065|122 128|E2 gene
P01429768T0000|5 23|neutrophil response
P01429836A0457|96 109|Vps1p function
P01429836A1205|13 17|Vps1p
P01429836A1205|73 87|protein sorting
P01431380A0244|147 163|group rickettsiae
P01431380A0244|164 167|SFGR
P01431380A0244|296 299|JSFR
P01431380A0244|369 372|SFGR
P01431602A0229|62 82|micrograms phosphorus
P01433391A0594|3 13|consequence
P01433502A1163|38 54|enhancer activity
P01433524A0788|51 53|IE1
P01435698A0000|63 65|AVG
P01435698A0000|90 93|PGI2
P01436261A0145|0 26|Subcutaneous administration
P01437562A0462|49 61|C.fasciculata
P01437562A0462|100 118|nucleotide sequence
P01447189A1546|21 29|RNK-Met-1
P01447189T0000|45 53|RNK-Met-1
P01448806A0135|0 13|Administration
P01448917A0775|81 88|CPMV RNA
P01448917A0775|123 145|clover mottle virus RNA
P01448917A0775|155 163|CPSMV RNA
P01449183A0795|28 44|transferrin assay
P01449301A0710|0 16|Cold cardioplegia
P01450815A0337|29 32|IPRK
P01450815A0337|69 71|RPF
P01450815A0337|75 77|GFR
P01451771A0619|114 116|PCA
P01451771A0619|153 155|MDS
P01452037A0000|26 65|glyceraldehyde-3-phosphate dehydrogenase
P01452037A0000|167 192|Bacillus megaterium DSM319
P01452584T0000|73 86|Lindberg Award
P01452703A0782|0 17|Laboratory studies
P01452703A0782|151 160|ELISA kits
P01454518A0336|135 159|stringency hybridizations
P01454518A0336|191 200|ERCC3 cDNA
P01454819A0000|65 96|arginine ADP-ribosyltransferases
P01454819A0000|186 207|ADP-ribosylation cycle
P01456888A0074|58 68|HIV-1 group
P01456888A0074|281 310|myristylation consensus signal
P01457380A0000|101 114|ttk transcript
P01458170A0155|0 9|Adapromine
P01458170A0155|115 117|EEG
P01459447A0484|5 13|sequences
P01459451A0478|68 83|co-antirepressor
P01459885A0705|13 33|haloperidol treatment
P01459921A0000|36 52|Hampshire wethers
P01460054A0478|105 122|DNA binding domain
P01460054A0968|10 14|ICSBP
P01460772T0001|65 84|interferon treatment
P01462786T0000|0 22|Dynamic decision making
P01464329T0000|61 80|prophase chromosomes
P01464606A0344|125 148|fragment affinity column
P01464606A0344|161 164|EDTA
P01467828A0542|52 66|opioid peptides
P01468625A0282|16 19|LEU2
P01468625A0282|23 32|HIS3 cDNAs
P01468625A1080|11 14|ACT1
P01468625A1080|39 42|NSR1
P01469042A0355|72 101|mouse centromere satellite DNA
P01469047A1606|61 90|% amino acid sequence identity
P01470243A0871|31 32|Ht
P01470243A0871|151 162|independence
P01470243A0871|231 243|haemodilution
P01470243A0871|265 280|viscosity effect
P01471602A0362|30 51|bile acid sequestrants
P01471602A0362|113 119|HMG-CoA
P01471602A0362|121 140|reductase inhibitors
P01473234A1001|0 11|Green pepper
P01474990A0000|30 32|DNA
P01476376T0000|0 4|Assay
P01477021A0394|42 70|serum prolactin concentration
P01478672A0795|37 55|alpha satellite DNA
P01480183A0000|30 45|lactoferrin gene
P01480183A1689|64 90|lactoferrin gene expression
P01482912A0617|38 48|HL7 message
P01483755A0000|8 29|resonance spectroscopy
P01483755A0000|30 32|MRS
P01483755A0000|45 47|MRI
P01485648A0000|50 69|Pharmacia CAP System
P01485648A0000|69 92|Pharmacia Diagnostics AB
P01486836A0774|17 19|VPA
P01486836A0774|49 70|visuomotor performance
P01486836A0774|117 138|visuomotor performance
P01487144A0505|107 130|transcription terminator
P01487144A0505|151 168|L cell fibroblasts
P01490493A0416|69 87|triglyceride levels
P01492463T0001|0 4|Alena
P01492463T0001|15 20|Prague
P01496348A0000|0 5|Caries
P01496784A0939|36 51|strongyloidiasis
P01498607A0000|79 112|parsley chalcone synthase promoter
P01499213A0185|65 85|hyperextension injury
P01499213A0185|141 156|L2-L3 disk space
P01499616A0136|169 181|foreskin flap
P01502157A0000|71 103|P2 transcription initiation sites
P01504853A0299|9 12|LHRH
P01505488A0231|41 43|EVL
P01505516A0928|56 69|valine residue
P01506746A0476|0 20|Greater rupture force
P01509798A0520|33 34|UT
P01509798A0520|52 53|AT
P01509798A0520|62 64|UEA
P01511231A0085|62 84|smoking cessation trial
P01511950T0000|96 122|hepatitis B surface antigen
P01512259A0867|104 110|Dfurin2
P01512654A0503|73 86|KLH challenges
P01513213A0231|0 16|Model predictions
P01513213A0231|74 82|HIP trial
P01513213A0231|128 135|HIP data
P01518833A0397|1 24|lambda gt10 cDNA library
P01518833A0397|48 50|RNA
P01518849A0165|150 187|alpha 1-proteinase inhibitor complexes
P01523111A0769|0 6|Factors
P01524549A0241|4 16|GH deficiency
P01524549A0241|114 126|GH deficiency
P01524549A0241|152 161|GH therapy
P01525153A0359|84 105|K cation concentration
P01526658A0454|0 2|IFI
P01526658A0454|86 95|B lineages
P01527020A0511|33 62|rat AdoMet decarboxylase genes
P01529530T0000|92 118|ISGF3 transcription complex
P01531086A0127|16 28|reading frame
P01531214A0885|9 12|LD50
P01531214A0885|21 26|RP-170
P01531632A0000|104 107|SSB1
P01531632A0000|111 114|NSR1
P01531632A0000|149 158|GAR domain
P01532229A1264|58 62|HF-1a
P01532229A1264|81 85|HF-1b
P01532229A1264|87 91|MEF-2
P01532796A0107|0 8|Mutations
P01532796A0107|137 144|Ackerman
P01532914A0067|21 40|hepatitis B vaccines
P01533760T0000|0 27|Estrogen replacement therapy
P01535242A0557|9 14|FDC-P1
P01535242A0557|16 24|MAC cells
P01535242A0557|43 48|GM-CSF
P01536153A0574|89 107|animal food workers
P01536153A0574|195 197|IgE
P01536575A1213|152 174|cytochrome P450IA1 gene
P01536575A1213|174 179|CYPIA1
P01536575A1213|204 228|detoxification/activation
P01537334A0507|60 85|coat colour mutation slaty
P01537845A0571|51 74|c-myb gene transcription
P01538401A1244|3 27|base-pair oligonucleotide
P01538401A1244|158 170|DNA fragments
P01538403A1058|184 204|H5 promoter mutations
P01539996A0588|38 59|T. thermophilus enzyme
P01539996A0588|290 311|T. thermophilus enzyme
P01541556A1040|101 114|Cys-22 residue
P01542565T0000|47 63|Nicotiana tabacum
P01542667A0125|15 23|IFN-gamma
P01542686A0000|62 86|p75 nucleoprotein complex
P01542730A1982|99 106|AV block
P01542730A1982|109 118|DDD pacing
P01542730A1982|198 201|DDDR
P01542730A1982|257 264|ABSTRACT
P01542730A1982|279 283|WORDS
P01543909A0787|30 39|K562 cells
P01544854A0699|29 37|WR-168643
P01544918A1240|39 73|8-azido-cAMP photoaffinity labeling
P01544918A1240|255 277|RII alpha dephosphoform
P01544928A1252|22 33|DNA sequence
P01545523A0000|16 30|quantifications
P01545523A0000|105 122|antistreptolysin O
P01545792A0000|29 33|MLC-2
P01545792A0492|87 110|MLC-2 gene transcription
P01545797A0587|0 19|Disruption mutations
P01545797A0587|43 51|SLK1 gene
P01545806T0000|49 74|recombination genes REC102
P01545818A0696|3 6|p130
P01545818A0696|10 12|p62
P01546522A0000|29 47|leukoencephalopathy
P01546522A0000|49 51|PML
P01547775A1024|168 197|ORF2a/ORF2b transframe protein
P01547942A0120|121 127|CHOP-10
P01548891A0635|62 78|thyroid carcinoma
P01548891A0635|115 131|thyroid carcinoma
P01549118A0000|3 43|Caenorhabditis elegans vitellogenin genes
P01549123A0480|3 11|MET4 gene
P01549125A0140|106 123|DNA binding assays
P01549465A0122|8 34|transactivation experiments
P01551176A0000|0 7|GR63178A
P01551568A1476|0 21|Marker rescue analysis
P01551898A1084|116 125|LAPP/liter
P01551910A0313|21 54|gel mobility shift electrophoresis
P01552052A0139|0 8|OBJECTIVE
P01552457T0000|0 23|Intrapocket chemotherapy
P01552662A0398|25 26|BF
P01552662A0398|77 79|LAD
P01554334A0000|37 45|IFN-gamma
P01555556A0565|0 14|Control Tmuscle
P01555556A0565|63 64|SD
P01556068A0000|3 32|Klebsiella aerogenes gene maoA
P01557411A1282|13 20|D1A gene
P01560021A0379|63 80|brain AE3 variants
P01562659A0676|198 211|CNS vasculitis
P01562659A0676|277 296|C. immitis infection
P01563343A0548|55 66|CAB promoter
P01563635T0000|48 72|M.HinfI methyltransferase
P01564653A0307|7 15|companies
P01565093A0179|136 162|disease surveillance system
P01565882A0737|49 50|RD
P01565882A0737|119 126|RD image
P01565882A0737|251 258|RD image
P01568960A1129|126 137|VA/Q regions
P01569015A0120|15 19|FRAME
P01569015A0120|67 70|ORFs
P01569102A0708|31 42|LDL receptor
P01569344A0404|97 116|HTLV-I/II prevalence
P01569581A0482|135 163|translation initiation region
P01569581A0482|183 214|translation initiation frequency
P01569584A0672|73 87|m6F6 cDNA clone
P01569945A0529|3 11|SEN1 gene
P01572549A0000|0 23|Protein tyrosine kinases
P01572549A0000|23 26|PTKs
P01572549A0000|168 190|growth factor receptors
P01573270A0000|152 172|EBV-B lymphocyte line
P01577056A0178|60 71|theophylline
P01577056A0178|169 182|washout period
P01577819A0709|10 30|PRP-precursor alleles
P01579472A1018|16 31|enhancer element
P01579537A0000|37 51|botulinum toxin
P01580738T0001|0 8|Allagille
P01581409A0398|45 64|Pharmacia CAP System
P01581409A0398|69 86|DPC AlaSTAT System
P01581965A0388|85 122|breakpoint cluster region gene product
P01582413A0192|173 183|DNA binding
P01582413A0192|186 207|hetero-oligomerization
P01582413A0759|141 151|DNA binding
P01584812T0000|100 126|transcription factor NGFI-C
P01585014A0000|108 133|progestagen sponge removal
P01585014A0000|359 382|mare serum gonadotrophin
P01585014A0000|382 385|PMSG
P01585014A0000|392 422|mg follicle stimulating hormone
P01585014A0000|421 425|FSH-P
P01587267A1144|52 56|X-ray
P01587763A0402|5 20|body irradiation
P01588270A1029|124 126|DBP
P01588315A0356|9 33|Orgyia pseudotsugata MNPV
P